drugset
drugset / Trial / NCT05488327

Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis

NCT05488327 ↗

Unknown 10 enrolled Jiangxi Provincial People's Hopital
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to evaluate the efficacy and safety of lenalidomide in the treatment of patients with active cutaneous DM.

Timeline

Start
2022-08-01
Primary completion
2023-08-01
Completion
2023-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 5 mg —

Indications

dermatomyositis